(Q39351514)

11 September 2017

title

Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence (English)

1 reference

11 September 2017

David R Staskin

1

1 reference

11 September 2017

Alexis E Te

series ordinal

2

1 reference

11 September 2017

publication date

1 June 2006

1 reference

11 September 2017

1 reference

11 September 2017

volume

97

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

1256-1261

1 reference

The impact on health‐related quality of life of stress, urge and mixed urinary incontinence

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

The role of professional associations in reducing maternal mortality worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

Influence of behavior modification on overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

Effects of estrogen with and without progestin on urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

A severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06150.X

10.1111/J.1464-410X.2006.06150.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference